Moreover, these EVs have demonstrated significant tumor growth inhibition and extended survival in multiple preclinical tumor models, including melanoma, liver cancer, and breast cancer, outperforming anti-DR5 antibodies. Here, TNFRSF10B is linked to breast carcinoma.